Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Research & Development (2016 - 2025)

Ultragenyx Pharmaceutical has reported Research & Development over the past 10 years, most recently at $203.3 million for Q4 2025.

  • Quarterly Research & Development rose 8.18% to $203.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $750.0 million through Dec 2025, up 7.45% year-over-year, with the annual reading at $750.0 million for FY2025, 7.45% up from the prior year.
  • Research & Development was $203.3 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $216.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $237.3 million in Q3 2022 and troughed at $113.2 million in Q2 2021.
  • The 5-year median for Research & Development is $164.8 million (2023), against an average of $164.9 million.
  • Year-over-year, Research & Development soared 490.07% in 2021 and then plummeted 33.73% in 2023.
  • A 5-year view of Research & Development shows it stood at $123.0 million in 2021, then skyrocketed by 38.85% to $170.8 million in 2022, then fell by 6.26% to $160.1 million in 2023, then grew by 17.36% to $187.9 million in 2024, then increased by 8.18% to $203.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Research & Development are $203.3 million (Q4 2025), $216.2 million (Q3 2025), and $164.7 million (Q2 2025).